Xenetic Biosciences, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023; filed August 10, 2023. Xenetic is a clinical-stage biopharmaceutical company focused on immune-oncology. It is prioritizing its DNase program for solid tumors; it also holds the XCART CAR-T platform and receives PolyXen royalties. No drug candidates have regulatory marketing approval.
Financial highlights
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Royalty revenue | $651,005 | $416,710 | $1,256,849 | $805,703 |
| Research and development expense | $903,243 | $2,077,499 | $1,498,519 | $3,178,898 |
| General and administrative expense | $945,950 | $1,026,290 | $1,871,693 | $1,933,599 |
| Operating loss | $1,198,188 | $2,687,079 | $2,113,363 | $4,306,794 |
| Net loss | $1,050,963 | $2,672,190 | $1,907,517 | $4,265,801 |
| Basic and diluted loss per share | $0.69 | $1.90 | $1.25 | $3.10 |
At June 30, 2023, cash was $10.7 million, total current assets were $12.0 million, current liabilities were $871,315, and total liabilities were $871,315. Working capital was approximately $11.2 million, versus $12.6 million at year-end 2022. Total assets were $12.7 million and stockholders’ equity was $11.9 million. The filing reports no debt balance; the Pharmsynthez loan was repaid in May 2023.
For the six months, operating cash use was $2.37 million, investing cash flow was zero, financing cash flow was zero, and cash declined $2.37 million. No gross profit or operating margin is separately presented; the filing reports royalty revenue and operating expenses.
Changes and notable items
- Royalty revenue rose 56.2% in Q2 and 56.0% for the first half, reflecting higher Takeda-related royalties.
- Reported R&D expense declined year over year, mainly because 2022 included a $1.305 million nonrecurring in-process R&D charge for the DNase license. Excluding that charge, Q2 R&D increased 16.9%; first-half R&D decreased 20.0%.
- Net loss narrowed year over year, alongside the revenue increase, lower reported expenses, and higher interest income. Six-month interest income was $180,204, versus $41,870 in 2022.
- The company effected a 1-for-10 reverse stock split on May 15, 2023, and regained Nasdaq minimum-bid-price compliance on May 30. The split resulted in 15,941 additional shares from fractional-share rounding. Common shares outstanding were 1,532,600 as of August 4, 2023.
- The company received approximately $65,000 of income related to interest and fees on the repaid Pharmsynthez loan during the first half.
Outlook, risks, and commitments
- Management expects continued near-term operating losses and states that the losses raise substantial doubt about the company’s ability to continue as a going concern. It nevertheless believes existing resources can fund operations for at least 12 months from the financial-statement issuance date; additional capital may be needed over the longer term, and future financing is uncertain.
- Management is directing resources to systemic DNase development, including preclinical work toward pancreatic carcinoma and other solid tumors. Development of XCART has been suspended. The filing gives no specific clinical milestones or financial guidance.
- The Catalent manufacturing project is estimated to cost up to approximately $5 million, excluding certain fees and alternatives, and is targeted for completion in the first half of 2024. Approximately $1.8 million had been paid by June 30, 2023, including $0.9 million recorded as a prepaid asset.
- A Scripps Research agreement provides for up to $938,000 in research funding; approximately $0.3 million had been paid by June 30, 2023. After quarter-end, Xenetic entered its first statement of work under the Volition collaboration.
- Key risks include clinical and development uncertainty, future financing needs, dependence on collaborators and manufacturers, and possible loss of Nasdaq listing compliance. The reverse split may reduce share liquidity. The filing reports no material legal proceedings and no material changes to previously disclosed risk factors other than those related to the reverse split and Nasdaq listing.
Investor verification points
- Confirm the cash runway assumptions behind management’s estimate of at least 12 months of funding and assess the potential need, timing, and dilution of future financing.
- Track DNase development progress, clinical-entry plans, spending priorities, and the suspended XCART program.
- Verify the durability and timing of Takeda royalty revenue and the basis for the reported year-over-year increase.
- Monitor Catalent and Scripps spending against their stated terms, timelines, and remaining commitments.
- Monitor Nasdaq listing compliance and the effect of the reverse split on share liquidity and capital-raising capacity.